• Explore /
  • Poster
  • / AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.

AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.

Abstract Poster

Authors

null

Nicoletta Colombo

University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy

Nicoletta Colombo , Maria Pilar Barretina-Ginesta , Philip James Beale , Kenichi Harano , Emma Hudson , Frederik Marmé , Christian Marth , Manuela Radaglio , Angeles Alvarez Secord , Roldano Fossati , Anna Roberto , Eliana Rulli , Francesca Tettamanzi , Elena Biagioli

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT03603184

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS5608)

DOI

10.1200/JCO.2019.37.15_suppl.TPS5608

Abstract #

TPS5608

Poster Bd #

424a

Abstract Disclosures

Similar Posters

First Author: Christian Marth

First Author: Florence Joly

First Author: Rebecca Dent

First Author: Toon Van Gorp